251 related articles for article (PubMed ID: 24762860)
21. Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
Wei YQ; Wang DG; Yang H; Cao H
PLoS One; 2015; 10(7):e0132561. PubMed ID: 26147597
[TBL] [Abstract][Full Text] [Related]
22. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
[TBL] [Abstract][Full Text] [Related]
23. Switching from prasugrel to clopidogrel based on Cytochrome P450 2C19 genotyping in East Asian patients stabilized after acute myocardial infarction.
Lee JH; Ahn SG; Lee JW; Youn YJ; Ahn MS; Kim JY; Yoo BS; Lee SH; Yoon J; Kim J; Choi E; Yoo SY; Hung OY; Samady H
Platelets; 2016 Jun; 27(4):301-7. PubMed ID: 26556524
[TBL] [Abstract][Full Text] [Related]
24. Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke.
Yi X; Lin J; Wang Y; Zhou Q; Wang C; Cheng W; Chi L
J Atheroscler Thromb; 2016 Oct; 23(10):1188-1200. PubMed ID: 26961113
[TBL] [Abstract][Full Text] [Related]
25. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.
Bhatt DL; Paré G; Eikelboom JW; Simonsen KL; Emison ES; Fox KA; Steg PG; Montalescot G; Bhakta N; Hacke W; Flather MD; Mak KH; Cacoub P; Creager MA; Berger PB; Steinhubl SR; Murugesan G; Mehta SR; Kottke-Marchant K; Lincoff AM; Topol EJ;
Eur Heart J; 2012 Sep; 33(17):2143-50. PubMed ID: 22450429
[TBL] [Abstract][Full Text] [Related]
26. Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates With Efficacy of Clopidogrel and Adverse Events on Patients With Ischemic Stroke.
Yi X; Wang Y; Lin J; Cheng W; Zhou Q; Wang C
Clin Appl Thromb Hemost; 2017 Oct; 23(7):761-768. PubMed ID: 27233747
[TBL] [Abstract][Full Text] [Related]
27. Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel.
Doll JA; Neely ML; Roe MT; Armstrong PW; White HD; Prabhakaran D; Winters KJ; Duvvuru S; Sundseth SS; Jakubowski JA; Gurbel PA; Bhatt DL; Ohman EM; Fox KAA;
J Am Coll Cardiol; 2016 Mar; 67(8):936-947. PubMed ID: 26916483
[TBL] [Abstract][Full Text] [Related]
28. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.
Zhang L; Chen Y; Jin Y; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Li X; Li Y; Zhang Y; Lu C; Yin T
Thromb Res; 2013 Jul; 132(1):81-7. PubMed ID: 23726091
[TBL] [Abstract][Full Text] [Related]
29. [Impact of CYP2C19 genotypes on antiplatelet therapy among Chinese patients with acute myocardial infarction after percutaneous coronary intervention].
Xu JJ; Tang XF; Song Y; Xu N; Yao Y; Wu Y; Zhang J; Gao Z; Chen J; Gao RL; Yang YJ; Yuan JQ
Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Feb; 45(2):116-120. PubMed ID: 28260316
[No Abstract] [Full Text] [Related]
30. Concomitant Use of Proton-Pump Inhibitors and Clopidogrel Increases the Risk of Adverse Outcomes in Patients With Ischemic Stroke Carrying Reduced-Function CYP2C19*2.
Yi X; Han Z; Zhou Q; Cheng W; Lin J; Wang C
Clin Appl Thromb Hemost; 2018 Jan; 24(1):55-62. PubMed ID: 27637911
[TBL] [Abstract][Full Text] [Related]
31. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Mega JL; Simon T; Collet JP; Anderson JL; Antman EM; Bliden K; Cannon CP; Danchin N; Giusti B; Gurbel P; Horne BD; Hulot JS; Kastrati A; Montalescot G; Neumann FJ; Shen L; Sibbing D; Steg PG; Trenk D; Wiviott SD; Sabatine MS
JAMA; 2010 Oct; 304(16):1821-30. PubMed ID: 20978260
[TBL] [Abstract][Full Text] [Related]
32. Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction.
Simon T; Steg PG; Becquemont L; Verstuyft C; Kotti S; Schiele F; Ferrari E; Drouet E; Grollier G; Danchin N
Clin Pharmacol Ther; 2011 Oct; 90(4):561-7. PubMed ID: 21918510
[TBL] [Abstract][Full Text] [Related]
33. Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events.
Tiroch KA; Sibbing D; Koch W; Roosen-Runge T; Mehilli J; Schömig A; Kastrati A
Am Heart J; 2010 Sep; 160(3):506-12. PubMed ID: 20826260
[TBL] [Abstract][Full Text] [Related]
34. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY
JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435
[TBL] [Abstract][Full Text] [Related]
35. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.
Bauer T; Bouman HJ; van Werkum JW; Ford NF; ten Berg JM; Taubert D
BMJ; 2011 Aug; 343():d4588. PubMed ID: 21816733
[TBL] [Abstract][Full Text] [Related]
36. CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population.
Xie X; Ma YT; Yang YN; Li XM; Ma X; Fu ZY; Zheng YY; Chen BD; Liu F
PLoS One; 2013; 8(3):e59344. PubMed ID: 23555019
[TBL] [Abstract][Full Text] [Related]
37. Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis.
Pan Y; Chen W; Xu Y; Yi X; Han Y; Yang Q; Li X; Huang L; Johnston SC; Zhao X; Liu L; Zhang Q; Wang G; Wang Y; Wang Y
Circulation; 2017 Jan; 135(1):21-33. PubMed ID: 27806998
[TBL] [Abstract][Full Text] [Related]
38. Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population.
Subraja K; Dkhar SA; Priyadharsini R; Ravindra BK; Shewade DG; Satheesh S; Sridhar MG; Narayan SK; Adithan C
Eur J Clin Pharmacol; 2013 Mar; 69(3):415-22. PubMed ID: 22955794
[TBL] [Abstract][Full Text] [Related]
39. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J
EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648
[TBL] [Abstract][Full Text] [Related]
40. Relationship between cytochrome P450 2C19*17 genotype distribution, platelet aggregation and bleeding risk in patients with blood stasis syndrome of coronary artery disease treated with clopidogrel.
Dai ZL; Chen H; Wu XY
Zhong Xi Yi Jie He Xue Bao; 2012 Jun; 10(6):647-54. PubMed ID: 22704413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
